More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated.

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

As every student of the Bible knows, you can learn a lot wandering the desert for 40 years. So, yes, (who am I to argue) I’ve learned a lot over my near-four decades navigating our sunny dunes. Still ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new ...

Today it is happening again with GLP1 agonists like Semaglutide with the brand names of Wegovy, Ozempic, and Rybelsus and similar drugs like Moujaro and Zepbound. And just like all the other weight ...

Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration ...

On October 21, Novo Nordisk announced positive news on the cardiovascular benefits of its oral glucagon-like peptide-1 receptor (GLP-1R) agonist, Rybelsus, which is currently approved for type 2 ...

The FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under ...

The study showed that Rybelsus, the company's oral form of semaglutide, slashed the risk of major cardiovascular events by 14% in type 2 diabetes patients who also face cardiovascular or kidney ...

The FDA has added a new warning to drugs including Ozempic and Wegovy, cautioning that patients taking the drugs may be at a ...